Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 176 people enrolled
- Started
- 1 May 2019
- Ended
- 15 Oct 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ibudilast
- Placebo Oral Tablet
- Record updated
- 2 February 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- abstinent from all drugs except marijuana and methamphetamine and have a negative urine drug screen on test days
- Meet diagnosis for recent Methamphetamine-Use Disorder (DSM-V) or does not meet any substance-use disorders
Who cannot take part
- Any recreational or prescriptive use of psychotropic medications
- rs6971 genotype that confers low translocator protein (TSPO) binding affinity to prevent unnecessary radiation exposure
- Participation in any drug study in the last 3 months
- Clinically significant neurological, endocrine, renal, hepatic, or systemic diseases that would compromise safe participation or confound outcomes
- Any psychiatric diagnoses or primary psychotic or mood disorders (past depression diagnoses allowed)
- Any drug use disorder diagnosis besides methamphetamine or tobacco
- Neurodegenerative diseases that present with neuroinflammation
- Liver disease requiring medication or medical treatment and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit
- Known sensitivity to ibudilast
- Left handed
- MRI contraindications
- Claustrophobia
- Women who are pregnant or breast-feeding
- More than 4 weeks abstinent from methamphetamine
Where in United States
- VA Portland Health Care System, Portland, ORPortland, United States
About the trial
What the trial wants to find out
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.
The 3 groups in the trial
- PlaceboPlacebo, for comparison
Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
Treatment: Placebo Oral Tablet
- IbudilastExisting treatment, for comparison
Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
- ControlsNo study treatment, for comparison
Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast
- Record updated
- 2 February 2026